(XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer

被引：0
|
作者：
Alu, M. [1 ]
Laudani, A. [1 ]
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Savio, G. [1 ]
Pepe, A. [1 ]
Arcuri, C. [1 ]
Cusimano, M. R. [1 ]
Calabria, C. [1 ]
Agostara, B. [1 ]
机构：
[1] Osped Oncol Maurizio Ascoli, Palermo, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71049-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3546
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [21] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [22] OXALIPLATIN PLUS CAPECITABINE (XELOX) AS FIRST-LINE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER: RESULTS OF A MONOCENTRIC EXPERIENCE
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Restuccia, M.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 90 - 90
  • [23] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [24] A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.
    Park, Y.
    Lee, J.
    Ryoo, B.
    Ryu, M.
    Yang, S.
    Kim, B.
    Shin, D.
    Chang, H.
    Kim, T.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [25] Comparison of efficacy and safety of capecitabine and oxaliplatin (CAPOX) with epirubicin, oxaliplatin plus capecitabine (EOX) as first line treatment for advanced gastric cancer (AGC), a randomized clinical study
    Kayal, Smita
    Pani, Chinmaya Kumar
    Biswajit, Dubashi
    Verma, Surendrakumar
    Sistla, Sarath Chandra
    Cyriac, Sunu Lazar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [27] The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study
    Watanabe, Takuya
    Nakayama, Goro
    Ishigure, Kiyoshi
    Hayashi, Naomi
    Yaguchi, Toyohisa
    Kojima, Hiroshi
    Tsuboi, Kenji
    Ito, Akihiro
    Deguchi, Tomohiro
    Sekiya, Masanori
    Tanaka, Chie
    Ando, Yuichi
    Ohashi, Norifumi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [28] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Phase II study of capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC)
    Cassinello, Javier
    Alvarez, Jose V.
    Garcia Lopez, Maria J.
    Pujol, Eduardo
    Colmenarejo, Antonio
    De Segovia, Fernando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    ANNALS OF ONCOLOGY, 2006, 17 : 116 - 117
  • [30] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    Ozcelik, M.
    Odabas, H.
    Ercelep, O.
    Yuksel, S.
    Mert, A. G.
    Aydin, D.
    Surmeli, H.
    Isik, D.
    Isik, S.
    Oyman, A.
    Ustaalioglu, B. B. Oven
    Aliustaoglu, M.
    Gumus, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06): : 617 - 624
12345